Stacks

Based on preclinical data available through 2026, BPC-157 and TB-500 drive tendon and ligament repair through mechanistically distinct angiogenic pathways — neither compound has been validated in a controlled human trial. BPC-157 operates via FAK-paxillin and VEGFR2 signalling at the injury site; TB-500 acts systemically through G-actin sequestration and endothelial progenitor cell recruitment. No head-to-head RCT exists.

No direct co-administration trial for semaglutide and thymosin alpha-1 (Tα1) exists as of 2026. The interaction map is built from each compound's independent pharmacology: semaglutide's GLP-1R–mediated anti-inflammatory signaling and Tα1's TLR-dependent immune priming operate through non-overlapping receptor systems, making a direct pharmacodynamic collision unlikely but formally uncharacterised.